

UC Irvine

UC Irvine Previously Published Works

Title

Frequent expansion of Plasmodium vivax Duffy Binding Protein in Ethiopia and its epidemiological significance

Permalink

<https://escholarship.org/uc/item/3c60f0gb>

Journal

PLOS Neglected Tropical Diseases, 13(9)

ISSN

1935-2727

Authors

Lo, Eugenia
Hostetler, Jessica B
Yewhalaw, Delenasaw
[et al.](#)

Publication Date

2019-09-01

DOI

10.1371/journal.pntd.0007222

Peer reviewed

RESEARCH ARTICLE

Frequent expansion of *Plasmodium vivax* Duffy Binding Protein in Ethiopia and its epidemiological significance

Eugenia Lo^{1*}, Jessica B. Hostetler², Delenasaw Yewhalaw³, Richard D. Pearson⁴, Muzamil M. A. Hamid⁵, Karthigayan Gunalan², Daniel Kepple¹, Anthony Ford⁶, Daniel A. Janies⁶, Julian C. Rayner⁴, Louis H. Miller^{2*}, Guiyun Yan^{7*}

1 Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States of America, **2** Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, **3** Department of Medical Laboratory Sciences and Pathology, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia, **4** Malaria Programme, Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom, **5** Department of Parasitology and Medical Entomology, University of Khartoum, Khartoum, Sudan, **6** Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC, United States of America, **7** Program in Public Health, College of Health Sciences, University of California at Irvine, Irvine, CA, United States of America

* eugenia.lo@uncc.edu (EL); lmiller@niaid.nih.gov (LHM); guiyun@uci.edu (GY)



OPEN ACCESS

Citation: Lo E, Hostetler JB, Yewhalaw D, Pearson RD, Hamid MMA, Gunalan K, et al. (2019) Frequent expansion of *Plasmodium vivax* Duffy Binding Protein in Ethiopia and its epidemiological significance. PLoS Negl Trop Dis 13(9): e0007222. <https://doi.org/10.1371/journal.pntd.0007222>

Editor: Photini Sinnis, Johns Hopkins Bloomberg School of Public Health, UNITED STATES

Received: February 5, 2019

Accepted: July 23, 2019

Published: September 11, 2019

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](https://creativecommons.org/licenses/by/4.0/) public domain dedication.

Data Availability Statement: Additional information is provided as supplementary data accompanies this paper. Sequence data of this study are deposited in the European Nucleotide Archive (ENA) and the accession number of each sample is listed in [Table 1](#).

Funding: This research was funded by National Institutes of Health (NIH R15 AI138002 to EL; NIH U19 AI129326 to GY; NIH R01 AI050243 to GY; D43 TW001505 to GY) and The Wellcome Trust 206194/Z/17/Z to JR. The funders had no role in

Abstract

Plasmodium vivax invasion of human erythrocytes depends on the Duffy Binding Protein (*PvDBP*) which interacts with the Duffy antigen. *PvDBP* copy number has been recently shown to vary between *P. vivax* isolates in Sub-Saharan Africa. However, the extent of *PvDBP* copy number variation, the type of *PvDBP* duplications, as well as its significance across broad samples are still unclear. We determined the prevalence and type of *PvDBP* duplications, as well as *PvDBP* copy number variation among 178 Ethiopian *P. vivax* isolates using a PCR-based diagnostic method, a novel quantitative real-time PCR assay and whole genome sequencing. For the 145 symptomatic samples, *PvDBP* duplications were detected in 95 isolates, of which 81 had the Cambodian and 14 Malagasy-type *PvDBP* duplications. *PvDBP* varied from 1 to >4 copies. Isolates with multiple *PvDBP* copies were found to be higher in symptomatic than asymptomatic infections. For the 33 asymptomatic samples, *PvDBP* was detected with two copies in two of the isolates, and both were the Cambodian-type *PvDBP* duplication. *PvDBP* copy number in Duffy-negative heterozygotes was not significantly different from that in Duffy-positives, providing no support for the hypothesis that increased copy number is a specific association with Duffy-negativity, although the number of Duffy-negatives was small and further sampling is required to test this association thoroughly.

Author summary

Plasmodium vivax invasion of human erythrocytes relies on interaction between the Duffy antigen and *P. vivax* Duffy Binding Protein (*PvDBP*). Whole genome sequences

study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

from *P. vivax* field isolates in Madagascar identified a duplication of the *PvDBP* gene and *PvDBP* duplication has also been detected in non-African *P. vivax*-endemic countries. Two types of *PvDBP* duplications have been reported, termed Cambodian and Malagasy-type duplications. Our study used a combination of PCR-based diagnostic method, a novel quantitative real-time PCR assay, and whole genome sequencing to determine the prevalence and type of *PvDBP* duplications, as well as *PvDBP* copy number on a broad number of *P. vivax* samples in Ethiopia. We found that over 65% of *P. vivax* isolated from the symptomatic infections were detected with *PvDBP* duplications and *PvDBP* varied from 1 to >4 copies. The majority of *PvDBP* duplications belongs to the Cambodian-type while the Malagasy-type duplications was also detected. For the asymptomatic infections, despite a small sample size, the majority of *P. vivax* were detected with a single-copy based on both PCR and qPCR assays. There was no significant difference in *PvDBP* copy number between Duffy-null heterozygote and Duffy-positive homozygote/heterozygote. Further investigation is needed with expanded Duffy-null homozygotes to examine the functional significance of *PvDBP* expansion.

Introduction

Plasmodium vivax and *P. falciparum* are the two major parasite species that cause clinical malaria worldwide. While *P. falciparum* causes most malaria mortality, *P. vivax* can also cause severe disease and, more rarely death [1,2]. *P. vivax* is prominent in India, Southeast Asia, and South America. By contrast, vivax malaria is rare in sub-Saharan Africa, with significant rates of infection only found in a few countries [3]. The rarity of this infection is tightly associated with high prevalence of Duffy negativity in West and Central Africa [4]. This association represents a classic example of innate resistance to a pathogen resulting from the absence of a receptor for the pathogen [5]. A point mutation in the GATA-1 transcription factor binding site of the Duffy antigen/receptor for chemokines (*DARC*) gene promoter eliminates Duffy antigen (Fy) expression on the RBC surface required for *P. vivax* invasion [6]. This phenomenon is thought to account for the lack of *P. vivax* malaria in sub-Saharan Africa.

In Ethiopia, *P. vivax* and *P. falciparum* account for approximately 40% and 60% of the malaria cases, respectively [7,8]. The proportion of Duffy negatives in Ethiopia is about 35% [9,10], considerably lower than that documented in West and Central Africa (>97%) [4]. About 20% of hospital patients presented with malaria symptoms are Duffy-negatives [10–11]. While Duffy negativity was previously thought to be associated with complete resistance to *P. vivax*, *P. vivax* infection in Duffy-negative individuals was confirmed unequivocally in Madagascar [12], and has also been observed in multiple other parts of Africa as well as other parts of the world [13–18].

Plasmodium vivax invasion of human erythrocytes relies on interaction between the Duffy antigen and *P. vivax* Duffy Binding Protein (*PvDBP*) [19–20], though other reticulocyte ligand-receptor have also been recently identified [21]. Our recent study has shown that mutations in *PvDBP* do not explain the ability of *P. vivax* parasites to infect Duffy-negative individuals [22], but there could be other molecular mechanisms at play. Whole genome sequences from *P. vivax* field isolates in Madagascar identified a duplication of the *PvDBP* gene [23] and *PvDBP* duplication has also been detected in non-African *P. vivax*-endemic countries [24, 25]. In Ethiopia, *PvDBP* expansion has been reported with a 79% prevalence in a recent analysis of 24 *P. vivax* genomes [26]. However, sample size was relatively limited and the extent of copy number variation among broad samples is still unclear. The high prevalence of *PvDBP*

duplications raises the possibility that it is linked to the ability of *P. vivax* to infect Duffy-negative individuals.

Two types of *PvDBP* duplications have been reported, termed Cambodian and Malagasy-type duplications based on the samples in which they were first described [23–24]. Both create a complete duplication of the *PvDBP* gene, but they differ in the sequence and length of the 3'-boundary of the linker region between the tandem copies of *PvDBP* [24]. In this study, we used whole genome sequencing and PCR-based diagnostic methods to determine the prevalence of both the Madagascar- and Cambodia-type *PvDBP* duplications in southwestern Ethiopia where a high incidence of *P. vivax* infections and a modest proportion of Duffy-null individuals co-occur. We compared *PvDBP* copy number between Duffy-null heterozygotes (*FyA/B^{ES}* or *FyB/B^{ES}*) and homozygotes (*FyB^{ES}/B^{ES}*), between symptomatic and asymptomatic infections, and explored the correlation of gene copy number with parasitemia, age, gender, ethnicity, and malaria symptoms in order to shed light on the epidemiological significance of *PvDBP* duplications.

Materials and methods

Ethics statement

Scientific and ethical clearance was given by the institutional scientific and ethical review boards of the Jimma University, Ethiopia, and University of North Carolina at Charlotte, USA. Written informed consent/assent for study participation was obtained from all consenting heads of households, parents/guardians (for minors under age of 18), and each individual who was willing to participate in the study. All experimental protocols were reviewed and approved by the institutional review board (IRB) of the University of North Carolina at Charlotte, USA and performed in accordance with the IRB guidelines and regulations.

Sample collection

A total of 178 *P. vivax* samples were included in this study. They were isolated from 145 symptomatic patients and 33 asymptomatic volunteers in Jimma, Ethiopia that had previously been confirmed by microscopy and PCR to be infected with *P. vivax* [9,10]. Symptomatic samples were obtained from patients who visited the health centers/hospitals in the Jimma town and presented with malaria signs/symptoms including axillary temperature $\geq 37^{\circ}\text{C}$, vomiting, diarrhea, nausea, abdominal pain, chills, fatigue, muscle pain, headache, malaise or loss of appetite (S1 Table). The asymptomatic samples were obtained from the community in the same area and had no fever or other malaria symptoms at the time of collection. Thick and thin blood smears were prepared for each subject to screen for *P. vivax* by microscopy. Parasites were counted against 200 leukocytes and a slide was considered negative when no parasites were observed after counting over 100 microscopic fields. All slides were read in duplicate by two microscopists at the time of sample collection. The density of parasitemia was expressed as the number of asexual *P. vivax* per microliter of blood, assuming a leukocyte count of 8000 per microliter. Three to four blood spots, each equivalent to $\sim 50\mu\text{l}$ of blood, were blotted on Whatman 3MM filter paper from each participating individual. Parasite DNA was extracted from dried blood spots by the Saponin/Chelex method [27] and genomic DNA was eluted in a total volume of 200 μl TE buffer. Eluted DNA was confirmed with *P. vivax* by nested and quantitative PCR using the 18S rRNA *P. vivax*-specific primers [10], prior to PCR diagnosis of *PvDBP* duplications and quantification of copy number.

For a subset of 20 symptomatic samples that were confirmed with *P. vivax*, 6ml whole blood was collected from the patients. We used the Lymphoprep/Plasmodipur-based protocol to deplete white cells and enrich red cells before DNA extraction [28]. DNA was extracted

from the enriched RBCs using the ZymoBead Genomic DNA kit (Zymo Research) following the manufacturer's procedures. Whole genome sequences were obtained for these samples on a HiSeq Illumina Sequencing Platform at the Wellcome Trust Sanger Institute (ENA accession number of each sample in Table 1). The generated sequence reads were mapped individually to the *P. vivax* PVP01 reference genome [29] using bwa version 0.5.9-r16 with default parameters [30]. The resulting assembly bam files were reviewed in the region containing *PvDBP* (chromosome 6: 976329–980090) using the Artemis genome viewer [31]. Using a “non-proper pair” read filter in Artemis, mate pairs that were oriented tail-to-tail indicated *PvDBP* duplications [24].

Quantification of *Plasmodium vivax* DNA

The amount of *P. vivax* DNA in each sample was estimated using the SYBR Green quantitative PCR detection method using primers that targeted the 18S rRNA genes of *P. vivax* [10]. Amplification was conducted in a 20 µl reaction mixture containing 1 µL of genomic DNA, 10 µl 2×SYBR Green qPCR Master Mix (Thermo Scientific), and 0.5 uM primer. The reactions were performed in CFX96 Touch™ Real-Time PCR Detection System (BIORAD), with an initial denaturation at 95°C for 3 min, followed by 45 cycles at 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min with a final 95°C for 10 sec. This was followed by a melting curve step of temperature ranging from 65°C to 95°C with 0.5°C increments to determine the melting temperature of the amplified product. Each assay included positive controls of *P. vivax* Pakchong (MRA-342G) and Nicaragua (MRA-340G) isolates, in addition to negative controls including uninfected samples and water. A standard curve was produced from a ten-fold dilution series of the control plasmids to determine the amplification efficiency. Melting curve analyses were performed for each amplified sample to confirm specific amplifications of the target sequence. A cut-off threshold of 0.02 fluorescence units that robustly represented the threshold cycle at the log-linear phase of the amplification and above the background noise was set to determine *Ct* value for each assay. The mean *Ct* value was calculated from three independent assays of each sample. Samples yielding *Ct* values higher than 40 (as indicated in the negative controls) were considered negative for *Plasmodium* species. The amount of parasite DNA in a sample was quantified using the follow equation: Parasite DNA (/uL) = $[2^{E \times (40 - Ct_{\text{sample}})} / 10]$; where *Ct* for the threshold cycle of the sample, and E for amplification efficiency; assuming 10,000 18S rRNA copies/mL (i.e., 10 copies/uL) in each *Plasmodium* genome [32].

PCR diagnosis of *PvDBP* duplications

Two sets of primers were used to examine the prevalence and type of *PvDBP* duplications following published protocols [23, 24]. The first set of primers includes AF+AR, BF+BR, and BF+AR [23]. Primers BF+AR amplify a 612-bp product that contains the junction between the *PvDBP* copies in isolates with the Malagasy-type duplications. The second set of primers includes AF2+AR2, BF+BR, and BF+AR2 [24]. Primers BF+AR2 amplify a 736-bp product that contains the junction between the *PvDBP* copies in isolates with the Cambodia-type duplication. This primer pair, in theory, should also amplify a 1584-bp product should there be Malagasy-type duplications. Without duplications, BF+AR and BF+AR2 primers are opposite-facing in the samples and thus do not amplify a product [24].

Estimation of *PvDBP* copy number by qRT-PCR

PvDBP copy number was measured with a SYBR Green qPCR detection method using primers (forward: 5'-AGGTGGCTTTTGAGAATGAA-3'; reverse: 5'-GAATCTCCTGGAACCTTCTC-3') designed between region II to III of *PvDBP* (PVX_110810). *Plasmodium vivax* aldolase,

Table 1. Information of whole genome sequences of 20 *Plasmodium vivax* isolates from Ethiopia. The European Nucleotide Archive (ENA) accession number for all files (ERP012186).

Blood sample	ENA accession number	Whole genome sequence							PCR diagnosis		qPCR GCN	
		All reads	<i>P. vivax</i> reads (%)	Average genome coverage	<i>PvDBP</i> coverage	<i>PvDBP</i> copy	Mate/Cvg support [§] (Yes/No)	Duplication type [23,24] (Cambodian/Malagasy)	Genome covered 15X (%)	Malagasy duplication BF+AR (Yes/No)*		Cambodia duplication BF+AR2 (Yes/No)*
BBH (1)-125	ERS849384	16104099	14765167 (92%)	83.11	352.9	4.25	Yes	Cambodian	99.6	No	Yes	4.30
BBH (1)-132	ERS2593850	295443478	269499723 (91%)	582.99	548.8	0.94	No	Single copy	98.5	No	No	1.14
BBH (1)-137	ERS2593862	15428892	12612040 (82%)	41.09	99.14	2.41	Yes	Cambodian	96.1	No	Yes	3.58
BBH (1)-153	ERS2593851	19596872	17206221 (88%)	57.34	149.17	2.6	Yes	Cambodian	97.6	No	Yes	3.86
BBH (1)-162	ERS2593852	322082372	32342978 (10%)	72.36	102.41	1.42	No	Single copy	98.5	No	No	0.93
HT(1)-144	ERS2593853	16508858	8025807 (49%)	28.52	30.73	1.08	No	Single copy	95.9	No	No	1.18
HT(1)-147	ERS2593863	118998744	97833898 (82%)	234.14	761.45	3.25	Yes	Cambodian	98	No	Yes	3.71
HT(2)-112	ERS2593864	44338048	23619451 (53%)	73.45	83.3	1.13	No	Single copy	97.6	No	No	1.20
JHC (1)-208	ERS2593865	381752146	294998614 (77%)	112.34	254.12	2.26	Yes	Cambodian	98.7	No	Yes	2.70
JHC (2)-100	ERS2593855	17622060	15958894 (91%)	56.23	166.06	2.95	Yes	Cambodian	97.3	No	Yes	3.24
MKH (1)-72	ERS2593857	17668719	14101177 (80%)	57.11	53.41	0.94	No	Single copy	97.2	No	No	1.28
MKH (2)-71	ERS2593866	217327926	208538370 (96%)	715.07	1746.88	2.44	Yes	Malagasy	98.5	Yes	No	3.69
SGH (1)-355	ERS2593858	18782232	17776334 (95%)	75.92	104.84	1.38	No	Single copy	97	No	No	1.54
SGH (1)-357	ERS2593859	82415713	51869956 (63%)	106.63	469.81	4.41	Yes	Malagasy	98	Yes	No	5.14
SGH (1)-331	ERS849385	17931182	16408183 (92%)	90.97	79.85	0.88	No	Single copy	99.7	No	No	1.00
SGH (1)-337	ERS2593867	16492008	7883420 (48%)	29.05	79.25	2.73	Yes	Cambodian	95	No	Yes	3.44
SGH (1)-358	ERS2593868	13579936	7433474 (55%)	27.75	80.08	2.89	Yes	Cambodian	95.8	No	Yes	3.86
SGH (1)-359	ERS2593869	24113148	15808023 (66%)	46.36	118.61	2.56	Yes	Cambodian	97.9	No	Yes	3.51
SGH (2)-103	ERS2593861	33312612	29984852 (90%)	123.54	272.61	2.21	Yes	Cambodian	97.8	No	Yes	4.40
SGH (2)-108	ERS2593871	6209652	4333558 (70%)	16.45	27.06	1.64	Yes	Cambodian	64.2	No	Yes	2.82

[§] 'Yes' indicates *PvDBP* duplication; 'No' indicates a single copy.

* 'Yes' indicates an amplification product was observed in the PCR; 'No' indicates no amplification was observed.

<https://doi.org/10.1371/journal.pntd.0007222.t001>

which is known to be a single-copy gene, was used as an internal reference to calculate gene copy number [33]. Two Cambodian isolates, Pv0430 and Pv0431, which were confirmed previously by whole genome sequencing to contain a single and two *PvDBP* copies [24], respectively, were included in each run as positive controls. Water was used as a no DNA control.

Amplification was conducted in a 20 μ L reaction mixture containing 1 μ L of genomic DNA (all samples was standardized to ~50 genomes/ μ L in each reaction based on 18S qPCR assay; S2 Table), 10 μ L 2 \times SYBR Green qPCR Master Mix (Thermo Scientific, USA), and 0.5 μ M of each primer. Reaction was performed in CFX96 Touch™ Real-Time PCR System (Bio-Rad) with an initial denaturation at 95°C for 3 min, followed by 45 cycles at 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min with a final 95°C for 10 sec [22]. This was followed by a melting curve step of temperature ranging from 65°C to 95°C with 0.5°C increments to determine the melting temperature of the amplified product. Each assay included an internal reference *P. vivax* aldolase as well as the negative controls (uninfected samples and water). Melting curve analyses were performed for each amplified sample to confirm specific amplifications of the target sequence. A cut-off threshold of 0.02 fluorescence units that robustly represented the threshold cycle at the log-linear phase of the amplification and above the background noise was set to determine Ct value for each assay. The amplification of the *P. vivax aldolase* and *PvDBP* gene fragments was optimized to obtain similar amplification efficiency. The mean Ct value and standard error was calculated from three independent assays of each sample (S3 Table). *PvDBP* copy number (*N*) was calculated with the equation previously used for *Pvmdr1* copy number estimation [33] as follow: $N = 2^{\Delta\Delta Ct \pm SD}$, where $\Delta\Delta Ct = (Ct_{pvaldo} - Ct_{pvdbp}) - (Ct_{pvaldo\ cal} - Ct_{pvdbp\ cal})$. The Ct_{pvaldo} and Ct_{pvdbp} are threshold cycle values for the *P. vivax aldolase* and *PvDBP* genes respectively, whereas Ct_{cal} is an average difference between Ct_{pvaldo} and Ct_{pvdbp} obtained for the positive control containing a single copy of the *P. vivax aldolase* and *PvDBP* gene fragments (i.e., the Cambodian isolate Pv0430 in this case). The SD value is a standard deviation calculated as follow: $SD = \sqrt{(S_{pvdbp}^2 + S_{pvaldo}^2 + S_{cal}^2)}$ where S_{pvdbp} and S_{pvaldo} are the standard deviations from the average Ct calculated for three replicates in the *P. vivax aldolase* and *PvDBP* gene amplifications. S_{cal} is an average standard deviation of the ΔCt values for the calibrator. The *PvDBP* copy number of each sample was assessed twice for validation.

Duffy blood group genotyping

For all *P. vivax* positive samples, a 1,100-bp fragment of the human Duffy blood group antigen gene that encompasses the GATA1 transcription factor-binding site of the gene promoter was amplified using published primers [12]. PCR reaction contained 20 μ L DreamTaq PCR Mastermix, 1 μ L DNA template, and 0.5 μ L each primer. PCR conditions were: 94°C for 2-min, followed by 35 cycles of 94°C for 20s, 58°C for 30s, and 68°C for 60s, followed by a 4-min extension. PCR products were sequenced and the chromatograms were visually inspected to determine the *Fy* genotypes (see Duffy blood group nomenclature in [34]).

Correlation analyses

A one-tailed t-test was used to test for the significance of differences in *PvDBP* copy number between symptomatic and asymptomatic *P. vivax* infections, as well as among Duffy genotypes. In addition, we calculated Pearson's correlation coefficient (r^2) in R for the associations of *PvDBP* copy number with parasitemia and age among the clinical samples. Samples were also stratified by gender and ethnicity to test if there was a significant difference in *PvDBP* copy number. Malaria symptoms including fever, chills, malaise, fatigue, muscle/joint pain, headache, nausea, vomit, diarrhea, abdomen pain, loss of appetite, and respiratory difficulty (dependent variables) were recorded as presence or absence for each of the patients. Principle component analyses were performed to show the variation of all variables among the samples with different *PvDBP* copy number using the logistic PCA function in R. A 3-dimensional PCA plot was constructed with the plot3d function from the rgl package.

Results

PvDBP duplications are common in Ethiopian *P. vivax* infections

To establish whether Cambodian or Malagasy-type *PvDBP* duplications were present in the sample population, whole genome sequences were obtained for a subset of 20 Ethiopian *P. vivax* samples using Illumina sequencing (Table 1). For these 20 samples, 13 to 381 million 150 bp pair-end reads were generated and 10–96% of these reads was mapped to the *P. vivax* reference genome PVP01. The average *P. vivax* genome coverage was 16–715× with over 95% of the genome covered by at least 15 reads in the majority of the samples. The average *PvDBP* coverage was 27–1746×, of which the sequence coverage of the *PvDBP* region was clearly higher than the flanking regions in some samples (S1 Fig). We further confirmed and identified the type of *PvDBP* duplications by mapping the paired-end reads in a tail-to-tail orientation, respectively, on the Malagasy M15 [23] and Cambodian PV0431 [24] reference genomes. Based on whole genome sequences of the duplication break points, two out of the 20 *P. vivax* samples contained the Malagasy-type and 11 contained the Cambodian-type duplications. The remaining had a single copy *PvDBP* (Table 1).

To test more extensively for *PvDBP* duplications, we used recently published diagnostic PCR primers [24]. These primers had previously been used to genotype 20 Ethiopian *P. vivax* symptomatic samples [24]. We genotyped an additional 158 (125 symptomatic and 33 asymptomatic) *P. vivax* samples, bringing the total tested samples to 178 across this and the previous study. All samples produced bands of the expected size of 650–700bp with the control primers AF/AR, BF/BR, and AF2/AR2 (Fig 1), indicating the presence of *PvDBP* in all isolates. Among them, 14 (9.7%) showed a fragment of ~600bp with the Malagasy duplication primers BF/AR (e.g., sample SGH(1)-357 in Fig 1), 81 (55.9%) showed a fragment of ~800bp with the Cambodian duplication primers BF/AR2 (e.g., BBH(1)-125 in Fig 1), and 50 (34.5%) showed no amplifications with either pair of primers (e.g., BBH(1)-132 in Fig 1), suggesting either they only contained a single copy of *PvDBP* or a duplication not detected by either primer pair. For




Fig 1. Ethiopian *P. vivax* samples contain both the Malagasy- and Cambodian-type duplications. AF/AR, BF/BR and AF2/AR2 are control primers where all samples indicated amplifications except the negative control sample. Sample SGH(1)-357 produced a band of ~650bp with BF/AR primers, indicative of a Malagasy *PvDBP* duplication. Sample BBH(1)-125 produced a band of ~750bp with BF/AR2 primers, indicative of a Cambodian *PvDBP* duplication. Sample BBH(1)-132 showed no amplification with both BF/AR and BF/AR2 primers, indicative of a single *PvDBP* region without any duplications. No bands were observed for DNA-negative control (-) in all amplifications.

<https://doi.org/10.1371/journal.pntd.0007222.g001>

the 14 samples that showed amplification with the Malagasy duplication primers BF/AR, two were amplified with the Cambodian primers BF/AR2 giving a ~1,500bp band.

A quantitative PCR (qPCR) assay reveals higher order copy number variants in some samples

To test whether additional duplication types not detected by these primer pairs were present, we developed a qPCR assay that compared the quantity of *PvDBP* products to that of a known single copy gene control, *P. vivax* aldolase. To validate the assay, we compared *PvDBP* copy numbers estimated by qPCR with those estimated by PCR diagnostic primers (BF/AR and BF/AR2) and from whole genome sequencing for the 20 samples that had been whole genome sequenced (Table 1). There was a significant correlation between these two metrics (Fig 2A), confirming that the qPCR assay was measuring changes in copy number. For 50 samples that showed no amplification with primers BF/AR and BF/AR2, indicative of a single copy gene, qPCR copy number estimates ranged from 0.85–1.77 (a median value of 1.17 ± 0.26 ; Fig 2B). Six of these samples had also been whole genome sequenced, and had fold-coverage of *PvDBP* ranging from 0.88–1.42, confirming the presence of only a single *PvDBP* copy (Table 1; Fig 2B). We therefore used qPCR estimates of >1.9 to score samples containing multiple *PvDBP* copies.

Among the 145 symptomatic samples, there were 95 samples with *PvDBP* qPCR copy number estimates >1.9 , and all of these also showed amplifications with BF/AR or BF/AR2 primers, confirming the presence of more than one *PvDBP* copy. qPCR estimates for these samples ranged from 1.90–6.91 (Fig 2B), suggesting that some samples might contain higher order amplifications. We subdivided these samples into two categories: (1) samples with value <3.5 were defined as 2–3 *PvDBP* copies and (2) samples with value ≥ 3.5 were defined as ≥ 4 *PvDBP* copies. By this definition, 71 samples had 2–3 *PvDBP* copies (48.9%; median value of 2.42 ± 0.49) and 24 had ≥ 4 *PvDBP* copies (16.5%; median value of 4.40 ± 0.89 ; Fig 2B). This is to our




Fig 2. Comparison of *PvDBP* copy number estimated using different approaches. (A) A scatter plot showing *PvDBP* copy number estimated by quantitative real-time polymerase chain reaction (y-axis) and by *PvDBP* coverage in whole genome sequencing (x-axis) of 20 symptomatic *P. vivax* samples. Regression coefficient and P-value were indicated. (B) A dot plot showing *PvDBP* copy number detected by quantitative real-time PCR of all 145 symptomatic *P. vivax* samples by three different copy number categories. The geometric median and standard deviation of the data were indicated.

<https://doi.org/10.1371/journal.pntd.0007222.g002>




Fig 3. Comparison of *PvDBP* copy number in symptomatic and asymptomatic *P. vivax* samples. *PvDBP* copy number was estimated by qPCR. The geometric median and stand deviation of the data were shown for each type of infection.

<https://doi.org/10.1371/journal.pntd.0007222.g003>

knowledge the first report of higher order *PvDBP* copy numbers in a large number of *P. vivax* isolates. *PvDBP* fold coverage estimated from whole genome sequences corroborated the qPCR results in 16 out of the 20 samples. In four samples, qPCR data estimated >4 *PvDBP* copies whereas whole genome sequencing data estimated 2–3 *PvDBP* copies (S4A Table). For these four samples, we used the fold-coverage based on the whole genome sequences to score their copy number category. In total, 95 of 145 symptomatic samples tested (65.5%) had more than a single copy of *PvDBP*.

For the 33 asymptomatic samples, two (6.1%) were found with multiple *PvDBP* copies (Fig 3; S4B Table). The qPCR data was further confirmed with the PCR diagnostic primers BF/AR and BF/AR2 for all the 33 asymptomatic samples (S4B Table). No amplification was observed in 31 samples, indicative of the absence of duplication. In two asymptomatic samples, amplification was observed with primers BF/AR2, indicative of the Cambodian-type duplication. Two *PvDBP* copies were detected by qPCR in these two asymptomatic samples. A ten-fold higher rate of multi-copy *PvDBP* infections was observed in symptomatic patients compared to the asymptomatic volunteers ($P < 0.001$).

***PvDBP* copy number expansion correlates with malaria symptoms**

Based on *DARC* gene sequences, 101 of 145 (69.7%) symptomatic *P. vivax*-infected samples were Duffy-null heterozygote (FyA/B^{ES} or FyB/B^{ES}), two (1.4%) were Duffy-null homozygote (FyB^{ES}/B^{ES}), 17 (11.7%) were Duffy-positive homozygote (FyA/A or FyB/B) and 25 (17.2%) were Duffy-positive heterozygote (FyA/B or FyB/X²; [S5 Table](#)). Significant differences were observed in *PvDBP* copy number between FyA/B^{ES} and FyB/B^{ES}, FyB/B and FyA/B, FyB/B^{ES} and FyA/B, as well as FyA/B^{ES} and FyB/B ([Fig 4](#)). While both being Duffy-null heterozygotes, FyA/B^{ES} indicated a significantly higher *PvDBP* copy number than FyB/B^{ES}. Among the Duffy-positives, heterozygote FyA/B had a significantly higher *PvDBP* copy number than homozygote FyB/B. The *PvDBP* copy number of Duffy-null homozygote FyB^{ES}/B^{ES} and Duffy-positive homozygote FyA/A was not compared with other Duffy genotypes because their sample size was too small to generate significant comparisons ([Fig 4](#)). The two asymptomatic samples detected with two *PvDBP* copies were both Duffy-null heterozygote (FyB/B^{ES}). The remaining samples with a single *PvDBP* copy comprised both Duffy-null heterozygote and Duffy-positive homozygote and heterozygote ([S5 Table](#)).

To investigate whether high *PvDBP* copy number increases invasion efficiency of the parasite, the association of parasite densities with *PvDBP* copy number was examined. No significant association was detected between *PvDBP* copy number and parasite densities in the symptomatic samples ([S2A Fig](#)). We did not examine this correlation in the asymptomatic samples because of the small sample size. Also, we do not have the parasitemia and demographic information of the asymptomatic samples. For the symptomatic samples, no significant association was detected between *PvDBP* copy number and age, gender, and ethnicity ([S2B–S2D Fig; S6 Table](#)). The PCA plot based on the first three principle components reflected 99.5% of the total variation from 12 recorded malaria symptoms ([Fig 5; S1 Table](#)). No clear cluster was observed among samples with a single or multiple *PvDBP* copies, suggesting that the symptoms of these patients did not relate to *PvDBP* copy number.

Discussion

PvDBP copy number variation has previously been studied primarily using PCR genotyping. In this study, we used a quantitative PCR method for estimating copy number, an approach used in several studies particularly related to human diseases [35]. The qPCR assay outcome was validated against PCR genotyping and whole genome sequencing methods. We are aware that difference in the amount of parasite DNA among samples, particularly that between symptomatic and asymptomatic infections, may influence the quantification of *PvDBP* copy number. Therefore, we standardized the amount of parasite DNA in each reaction based on the results of 18S rRNA quantification prior to *PvDBP* qPCR assay. Also, for each sample we used the single-copy *P. vivax aldolase* gene as internal standard to calibrate and calculate the *PvDBP* gene copy number. Given that the results of *PvDBP* qPCR were consistent with those by PCR genotyping and whole genome sequencing, we are confident that the estimated *PvDBP* copy number was not biased by the amount of parasite DNA in our samples. Quantitative PCR offers a time- and cost-effective approach to analyze a large number of samples, as unlike whole genome sequencing, it can be performed with relatively little DNA, such as dried blood samples routinely taken in malaria studies. The genotyping PCR method used in previous studies of *PvDBP* copy number has the advantage of providing better detection of *PvDBP* duplications in polyclonal infections [23, 24]. However, this method is limited to identifying only presence or absence of *PvDBP* duplications rather than copy number variants as by qPCR method [36].




Fig 4. Comparison of *PvDBP* copy number among symptomatic samples with different Duffy genotypes. These included Duffy-null homozygotes (FyB^{ES}/B^{ES}), Duffy-null heterozygotes (FyA/B^{ES} or FyB/B^{ES}), Duffy-positive homozygotes (FyA/A or FyB/B), and Duffy-positive heterozygotes (FyA/B or $FyB/X2$). The geometric median and stand deviation of the data were shown for each of the genotypes.

<https://doi.org/10.1371/journal.pntd.0007222.g004>

PvDBP duplications detected with specific PCR primers correlated strongly with qPCR estimation of copy number. Samples that showed no amplifications by primers BF/AR (Malagasy-type) [23] or BF/AR2 (Cambodian-type) [24] were all estimated to contain a single copy of *PvDBP* by qPCR. A previous small scale test of only 25 Ethiopian *P. vivax* samples suggested that multi-copy *PvDBP* infections are more common in Ethiopia than in other parts of the




Fig 5. Scatter plot based on principle component analyses showing variation in malaria symptoms among the *P. vivax* patients. *PvDBP* copy number of *P. vivax* observed in each of the patient samples was indicated by different color circles. The first three axes represented 99.5% of the total variation from 12 malaria symptoms. No clear cluster was observed among samples with single or multiple *PvDBP* copies, suggesting that malaria symptoms of these patients did not relate to *PvDBP* copy number. Malaria symptom data are presented in [S3 Table](#).

<https://doi.org/10.1371/journal.pntd.0007222.g005>

world [24, 26]; increasing to 178 samples in this study confirms this finding. Genotyping 178 samples in total revealed that 65% of the Ethiopian isolates contained multiple *PvDBP* copies, which is considerably more than any other *P. vivax* location, as indicated previously in a worldwide study that included only very few samples from Ethiopia [24, 26]—this study provides more statistical robustness to that finding. It is formally possible that qPCR estimates of copy number could be complicated by the presence of mixed infections, where qPCR would generate an estimate that averages all clones present. However, in a previous study, *P. vivax* infections in Ethiopia including Jimma were found to have a relatively low polyclonality rate (4.3%) based on microsatellite typing [9]. The twenty samples in this study were confirmed as monoclonal by microsatellites prior to whole genome sequencing. In *P. vivax*-endemic area like Papua, Indonesia, asymptomatic samples have been showed with higher multiplicity of infection and percentage of polyclonality than symptomatic samples based on microsatellite

markers [37]. Although *P. vivax* is not highly endemic in our study sites in Jimma, Ethiopia, we cannot rule out the possibility that such differences may occur between our symptomatic and asymptomatic samples and affect the comparison of *PvDBP* amplifications.

Cambodian-type duplications were five-times more common than the Malagasy-type. Although primers BF/AR2 were used to diagnose the presence of the Cambodian-type *PvDBP* duplications, this primer pair can also produce a 1,584-bp amplicon should there be Malagasy-type duplications [24]. Among the 14 samples that were diagnosed with the Malagasy-type duplications based on BF/AR, only two were detected with a 1,584-bp amplicon by BF/AR2, likely due to limited quality of DNA extracted from dried blood on filter papers. The preponderance of the Cambodian-type duplications among our samples corroborated the finding by Auburn *et al.* [26] that indicated a 63% prevalence of the Cambodian-type duplications among 24 *P. vivax* isolates in Ethiopia. This finding suggested that *PvDBP* duplications observed in the Ethiopian isolates may have arisen independently through local selection and adaptation, or derived from Southeast Asia after *P. vivax* was re-introduced back to Africa [38, 39]. It is possible that *P. vivax* with expanded *PvDBP* acquired better fitness and spread through Africa where the majority of populations are Duffy-negative [3]. Though less common, the presence of the Malagasy-type duplications in Ethiopian *P. vivax* may reflect a contemporary gene exchange between populations via human movement.

More than four copies were detected in some of the Ethiopian isolates, higher than that reported in Madagascar (up to two copies) [23] and Southeast Asia (two and three copies) [24, 25]. Our findings were consistent with earlier studies that reported high-order *PvDBP* copies among a smaller number of *P. vivax* samples in Ethiopia [22, 26]. Gene duplication can generate new gene functions or alter gene expression patterns [40]. For examples, in *P. knowlesi* duplication of *PkDBP*-alpha and deletion of *PkDBP*-gamma allow the parasite to invade human erythrocytes that lack surface Neu5Gc, a form of sialic acid *P. knowlesi* requires for binding [41]. In *P. falciparum*, duplications of the *Pfmdr1* gene resulted in increased resistance to antimalarial drug mefloquine [42–45]. While we did not detect any formal association between *PvDBP* copy number and Duffy negativity, it is worth noting that in other parts of the world such as Cambodia, India, and Brazil where only a small proportion of Duffy-negative individuals live, *PvDBP* expansion was observed with much lower frequency [24], with the exception of such in Thailand where a moderate rate (30%) of *PvDBP* duplications was observed [26]. Apart from *PvDBP*, another gene *PvEBP*, which harbors all the hallmarks of a *Plasmodium* red blood cell invasion protein, including conserved Duffy-binding like and C-terminal cysteine-rich domains [46], has been recently shown to be variable in copy number among the Malagasy *P. vivax* [47]. Functional analyses indicated that region II of this gene bound to both Duffy-positive and Duffy-negative reticulocytes, although at a lower frequency compared to *PvDBP*, suggestive of its role in erythrocyte invasion [48]. While we detected only a single copy of *PvEBP* in the 20 Ethiopian *P. vivax* samples based on whole genome sequences, further investigation is needed on a larger sample. The functional significance of *PvDBP* expansion merits further investigations through comparison of gene expression patterns and *in-vitro* binding assay of varying *PvDBP* dosage, and study of *P. vivax* isolates from Duffy negative individuals is clearly a high priority.

While we observed no association with Duffy negativity, with the clear caveat that Duffy negative sample numbers were limited, we did observe a statistically significant higher number of *P. vivax* isolates with multiple *PvDBP* copies in FyA/FyB^{ES} compared to FyB/FyB^{ES} and FyB/FyB, as well as FyA/B compared to FyB/FyB^{ES} and FyB/B. Given that *PvDBP* has a higher binding affinity with erythrocytes expressing the FyB than the FyA antigens [49], it is possible that *P. vivax* expanded the *PvDBP* gene into multiple copies in order to increase binding affinity to erythrocytes that express FyA antigen. The observation of a low number of *P. vivax*

infections in the FyA/A patients in this study lends support to the association between FyA antigen and a reduced risk of clinical vivax malaria in humans [49, 50]. While Duffy-negative heterozygotes in Papua New Guinea and the Brazilian Amazon region were previously shown with reduced erythrocyte susceptibility to *P. vivax* infection [51, 52] and a higher level of anti-*PvDBP* antibodies compared to Duffy-positives [53], the relative high proportion of Duffy-null heterozygotes (FyA/FyB^{ES} and FyB/FyB^{ES}) among our *P. vivax*-infected patients suggested that some lineages of *P. vivax* (such as those in Ethiopia) may have evolved with higher binding or invasion efficiency to erythrocytes with reduced Duffy antigen expression, perhaps through *PvDBP* expansion. In addition, we also observed a statistically significant higher number of *P. vivax* isolates with multiple *PvDBP* copies in symptomatic infections compared to asymptomatic infections. It is therefore possible that increased expression of *PvDBP* as a result of gene expansion may play a role in evading the immune response developed by the infected individuals, leading to symptoms. Further study with higher numbers of asymptomatic samples is needed to draw a definite conclusion. Moreover, symptoms and parasitemia of the samples were measured only at the initial stage of the infection rather than at various follow-up time intervals. Thus, it is yet unclear if high *PvDBP* copies of the parasites will increase the duration and/or severity of symptoms in the infected individuals over time. Given that age, gender and ethnicity did not correlate with *PvDBP* copy number, parasites with single or higher *PvDBP* copies could all cause infection equally within the host population.

To conclude, an exceptionally high prevalence of *PvDBP* expansion was observed among Ethiopian *P. vivax* isolates, of which the majority were Cambodian-type duplications, and higher order *PvDBP* copy number variants were identified by both qPCR and whole genome sequencing. Duffy-negative heterozygotes did not show a significantly higher *PvDBP* copy number than the Duffy-positives, but symptomatic infections had a significantly higher copy number than the asymptomatic ones. For the symptomatic samples, *PvDBP* copy number was not significantly associated with parasite density, age, gender and ethnicity. The functional significance of common *PvDBP* expansion and the presence of high copy number variants among the Ethiopian *P. vivax* are unclear. Our ongoing investigations focus on *PvDBP* copy number variation in expanded Duffy-negative homozygote individuals. *PvDBP* copy number in homozygous Duffy-negative infections and its correlation with symptoms are yet to be explored.

Supporting information

S1 Table. Presence or absence of malaria signs/symptoms among *P. vivax* patients.
(XLSX)

S2 Table. Mean Ct value of three independent quantitative real-time PCR assays of *P. vivax* 18S rRNA and the estimated parasite genomes per uL of samples including 145 symptomatic patients and 33 asymptomatic volunteers.
(XLSX)

S3 Table. Mean Ct value of three independent quantitative real-time PCR assays of *PvDBP* and *Pv aldolase* of 145 symptomatic patients and 33 asymptomatic volunteers. Asterisk indicates samples with multiple *PvDBP* copies.
(XLSX)

S4 Table. (A) Results of *PvDBP* duplications based on PCR and copy number estimated by quantitative real-time PCR and whole genome sequencing of *P. vivax* in the 145 symptomatic patient samples; (B) Results of PCR diagnosis and copy number estimated by quantitative real-

time PCR of *P. vivax* in the 33 asymptomatic volunteer samples.
(XLSX)

S5 Table. Duffy genotypes based on *DARC* sequences of (A) the 145 symptomatic patients and (B) 33 asymptomatic volunteers.
(XLSX)

S6 Table. Demographic information of the 145 *P. vivax*-infected symptomatic patients included in this study.
(XLSX)

S1 Fig. Coverage view showing mapped reads of sample BBH(1)-125 (blue line) with four-fold higher coverage than sample SGH(1)-331 (red line) with respect to *P. vivax* Sal-1 chromosome 6 region containing *PvDBP* (red box) using the Artemis genome browser.
(TIF)

S2 Fig. Association plots showing the non-significant correlation of *PvDBP* gene copy number with (1) parasitemia level, (B) age, (C) gender, and (D) ethnicity of the *P. vivax* samples.
(TIF)

Acknowledgments

We are greatly indebted to the staffs and technicians from Jimma University for field sample collection, the communities and hospitals for their support and willingness to participate in this research.

Author Contributions

Conceptualization: Eugenia Lo, Jessica B. Hostetler, Delenasaw Yewhalaw, Muzamil M. A. Hamid, Julian C. Rayner, Louis H. Miller, Guiyun Yan.

Data curation: Eugenia Lo, Jessica B. Hostetler, Delenasaw Yewhalaw, Muzamil M. A. Hamid, Daniel Kepple, Anthony Ford, Daniel A. Janies.

Formal analysis: Eugenia Lo, Jessica B. Hostetler, Richard D. Pearson, Anthony Ford, Daniel A. Janies.

Funding acquisition: Eugenia Lo, Julian C. Rayner, Guiyun Yan.

Investigation: Eugenia Lo, Jessica B. Hostetler, Muzamil M. A. Hamid, Karthigayan Gunalan, Julian C. Rayner, Louis H. Miller, Guiyun Yan.

Methodology: Eugenia Lo, Jessica B. Hostetler, Richard D. Pearson, Karthigayan Gunalan.

Project administration: Eugenia Lo, Delenasaw Yewhalaw, Guiyun Yan.

Resources: Eugenia Lo, Delenasaw Yewhalaw, Julian C. Rayner, Guiyun Yan.

Supervision: Eugenia Lo, Louis H. Miller, Guiyun Yan.

Validation: Eugenia Lo, Jessica B. Hostetler, Julian C. Rayner.

Visualization: Eugenia Lo.

Writing – original draft: Eugenia Lo.

Writing – review & editing: Eugenia Lo, Karthigayan Gunalan, Julian C. Rayner, Louis H. Miller, Guiyun Yan.

References

1. Kochar DK, Saxena V, Singh N, et al. *Plasmodium vivax* malaria. *Emerg. Infect. Dis.* 11,132–4 (2005). <https://doi.org/10.3201/eid1101.040519> PMID: 15705338
2. Gething PW, Elyazar IRF, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: *Plasmodium vivax* endemicity in 2010. *PLoS Negl. Trop. Dis.* 6, e1814 (2012). <https://doi.org/10.1371/journal.pntd.0001814> PMID: 22970336
3. Howes RE, Reiner RC Jr., Battle KE, Longbottom J, Mappin B, Ordanovich D, et al. *Plasmodium vivax* transmission in Africa. *PLoS Negl. Trop. Dis.* 9, e0004222 (2015). <https://doi.org/10.1371/journal.pntd.0004222> PMID: 26587988
4. Howes RE, Patil AP, Piel FB et al. The global distribution of the Duffy blood group. *Nat. Commun.* 2, 266 (2011). <https://doi.org/10.1038/ncomms1265> PMID: 21468018
5. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype, FyFy. *N. Engl. J. Med.* 295, 302–304 (1976). <https://doi.org/10.1056/NEJM197608052950602> PMID: 778616
6. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. *Nat. Genet.* 10, 224–228 (1995). <https://doi.org/10.1038/ng0695-224> PMID: 7663520
7. RBM: Risk of malaria epidemics in Ethiopia. The Roll Back Malaria Partnership, World Health Organization, Geneva, Switzerland. available at <http://www.rollbackmalaria.org/defeatmalaria/welcome/ethiopia>.
8. Ayele D, Zewotir T, Mwambi H. Prevalence and risk factors of malaria in Ethiopia. *Malar. J.* 11, 195 (2012). <https://doi.org/10.1186/1475-2875-11-195> PMID: 22691364
9. Lo EYY, Hemming-Schroeder E, Yewhalaw D, Nguyen J, Kebede E, Zemene E, et al. Transmission dynamics of co-endemic *Plasmodium vivax* and *P. falciparum* in Ethiopia and prevalence of antimalarial resistant genotypes. *PLoS Negl. Trop. Dis.* 11, e0005806 (2017). <https://doi.org/10.1371/journal.pntd.0005806> PMID: 28746333
10. Lo EYY, Delenasaw Y, Zhong D, et al. Molecular epidemiology of *Plasmodium vivax* and *Plasmodium falciparum* malaria among Duffy-positive and Duffy-negative populations in Ethiopia. *Malar. J.* 14, 84–94 (2015). <https://doi.org/10.1186/s12936-015-0596-4> PMID: 25884875
11. Woldearegai TG, Kreamsner PG, Kun JF, Mordmuller B. *Plasmodium vivax* malaria in Duffy negative individuals from Ethiopia. *Trans. R. Soc. Trop. Med. Hyg.* 107, 328–31 (2013). <https://doi.org/10.1093/trstmh/trt016> PMID: 23584375
12. Menard D, Barnadas C, Bouchier C, et al. *Plasmodium vivax* clinical malaria is commonly observed in Duffy-negative Malagasy people. *Proc. Natl. Acad. Sci. USA* 107, 5967–5971 (2010). <https://doi.org/10.1073/pnas.0912496107> PMID: 20231434
13. Mendes C, Dias F, Figueiredo J, et al. Duffy negative antigen is no longer a barrier to *Plasmodium vivax*-molecular evidences from the African West Coast (Angola and Equatorial Guinea). *PLoS Negl. Trop. Dis.* 5, e1192 (2011). <https://doi.org/10.1371/journal.pntd.0001192> PMID: 21713024
14. Poirier P, Doderer-Lang C, Atchade PS, et al. The hide and seek of *Plasmodium vivax* in West Africa: report from a large-scale study in Beninese asymptomatic subjects. *Malar. J.* 15, 570 (2016). <https://doi.org/10.1186/s12936-016-1620-z> PMID: 27887647
15. Russo G, Faggiono G, Paganoti GM, et al. Molecular evidence of *Plasmodium vivax* infection in Duffy negative symptomatic individuals from Dschang, West Cameroon. *Malar. J.* 16,74 (2017). <https://doi.org/10.1186/s12936-017-1722-2> PMID: 28196496
16. Niangaly A, Gunalan K, Ouattara A, et al. *Plasmodium vivax* infections over 3 years in Duffy blood group negative Malians in Bandiagara, Mali. *Am. J. Trop. Med. Hyg.* 97, 744 (2017). <https://doi.org/10.4269/ajtmh.17-0254> PMID: 28749772
17. Abdelraheem MH, Albsheer MMA, Mohamed HS, Aminet al. Transmission of *Plasmodium vivax* in Duffy-negative individuals in central Sudan. *Trans. R. Soc. Trop. Med. Hyg.* 11, 258–260 (2016).
18. Wurtz N, Mint Lekweiry K, Bogreau H, et al. *Vivax* malaria in Mauritania includes infection of a Duffy-negative individual. *Malar. J.* 10, 336 (2011). <https://doi.org/10.1186/1475-2875-10-336> PMID: 22050867
19. Beeson JG, Crabb BS. Towards a vaccine against *Plasmodium vivax* malaria. *PLoS Med.* 4, e350 (2007). <https://doi.org/10.1371/journal.pmed.0040350> PMID: 18092888
20. Batchelor JD, Malpede BM, Omattage NS, et al. Red blood cell invasion by *Plasmodium vivax*: structural basis for DBP engagement of DARC. *PLoS Pathog.* 10, e1003869 (2014). <https://doi.org/10.1371/journal.ppat.1003869> PMID: 24415938

21. Gruszczyk J, Kanjee U, Chan LJ, et al. Transferrin receptor 1 is a reticulocyte-specific receptor for *Plasmodium vivax*. *Science* 359, 48 (2018). <https://doi.org/10.1126/science.aan1078> PMID: 29302006
22. Gunalan K, Lo E, Hostetler JB, et al. Role of *Plasmodium vivax* Duffy-binding protein 1 in invasion of Duffy-null Africans. *Proc. Natl. Acad. Sci. USA* 113, 6271 (2016). <https://doi.org/10.1073/pnas.1606113113> PMID: 27190089
23. Menard D, Chan ER, Benedet C, et al. Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy *Plasmodium vivax* strains. *PLoS Negl. Trop. Dis.* 7, e2489 (2013). <https://doi.org/10.1371/journal.pntd.0002489> PMID: 24278487
24. Hostetler JH, Lo E, Kanjee U, et al. Independent origin and global spread of distinct duplications in the *Plasmodium vivax* Duffy Binding Protein gene. *PLoS Negl. Trop. Dis.* 10, e5091 (2016).
25. Pearson RD, Amato R, Auburn S, et al. Genomic analysis of local variation and recent evolution in *Plasmodium vivax*. *Nat. Genet.* 48, 959–964 (2016). <https://doi.org/10.1038/ng.3599> PMID: 27348299
26. Auburn S, Getachew S, Pearson RD, Amato R, Miotto O, Trimarsanto H, et al. Genomic analysis of *Plasmodium vivax* in Southern Ethiopia reveals selective pressures in multiple parasite mechanisms. *J. Infect. Dis.* (2019).
27. Berczky S, Martensson A, Gil JP, Farnert A. Short report: rapid DNA extraction from archive blood spots on filter paper for genotyping of *Plasmodium falciparum*. *Am. J. Trop. Med. Hyg.* 72, 249–51 (2005). PMID: 15772315
28. Sriprawat K, Kaewpongsri S, Suwanarusk R, et al. Effective and cheap removal of leukocytes and platelets from *Plasmodium vivax* infected blood. *Malar. J.* 8, 115 (2009). <https://doi.org/10.1186/1475-2875-8-115> PMID: 19490618
29. Auburn S, Bohme U, Steinbiss S, et al. A new *Plasmodium vivax* reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes. *Wellcome Open Res.* 15, 1 (2016).
30. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–60 (2009). <https://doi.org/10.1093/bioinformatics/btp324> PMID: 19451168
31. Carver T, Harris AR, Berriman M, et al. Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental data. *Bioinformatics* 28, 464–469 (2012). <https://doi.org/10.1093/bioinformatics/btr703> PMID: 22199388
32. Murphy SC, Prentice JL, Williamson K, Wallis CK, Fang FC, Fried M, Pinzon C, Wang R, Talley AK, Kappe SHI, Duffy PE, and Cookson BT. Real-Time quantitative reverse transcription PCR for monitoring of blood-stage *Plasmodium falciparum* infections in malaria human challenge trial. *Am. J. Trop. Med. Hyg.* 86, 383–394 (2012). <https://doi.org/10.4269/ajtmh.2012.10-0658> PMID: 22403305
33. Suwanarusk R, Russell B, Chavchich M, et al. Chloroquine Resistant *Plasmodium vivax*: In Vitro characterization and association with molecular polymorphisms. *PLoS ONE* 2, e1089 (2007). <https://doi.org/10.1371/journal.pone.0001089> PMID: 17971853
34. Wurtz N, Lekweiry KM, Bogreau H, Pradines B, Rogier C, Boukhary AOMS, Hafid JE, Salem MSA, Trape JF, Basco LK and Briolant S. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. *Malaria Journal* 10, 336 (2011). <https://doi.org/10.1186/1475-2875-10-336>
35. Sudmant PH, Kitzman JO, Antonacci F, et al. Diversity of human copy number variation and multicopy genes. *Science* 330, 641–646 (2010). <https://doi.org/10.1126/science.1197005> PMID: 21030649
36. Fernandez-Jimenez N, Castellanos-Rubio A, Plaza-Izurietta L, et al. Accuracy in copy number calling by qPCR and PRT: A matter of DNA. *PLoS ONE* 6, e28910 (2011). <https://doi.org/10.1371/journal.pone.0028910> PMID: 22174923
37. Pava Z, Handayani I, Trianty L, Utami RAS, Tirta YK, Puspitasari AM, et al. Passively versus actively detected malaria: similar genetic diversity but different complexity of infection. *Am. J. Trop. Med. Hyg.* 97, 1788–1796 (2017). <https://doi.org/10.4269/ajtmh.17-0364> PMID: 29016343
38. Mu J, Joy DA, Duan J, Huang Y, Carlton J, Walker J, et al. Host switch leads to emergence of *Plasmodium vivax* malaria in humans. *Mol. Biol. Evol.* 22, 1686 (2005). <https://doi.org/10.1093/molbev/msi160> PMID: 15858201
39. Hupalo DN, Luo Z, Menikov A, et al. Population genomics studies identify signatures of global dispersal and drug resistance in *Plasmodium vivax*. *Nat. Genet.* 48, 953–8 (2016). <https://doi.org/10.1038/ng.3588> PMID: 27348298
40. Lynch M, Conery JS. The evolutionary demography of duplicate genes. *J. Struct. Funct. Genomics* 3, 35–44 (2003). PMID: 12836683
41. Dankwa S, Lim C, Bei AK, et al. Ancient human sialic acid variant restricts an emerging zoonotic malaria parasite. *Nat. Comm.* 7, 11187 (2016).
42. Preechapornkul P, Imwong M, Chotivanich K et al. *Plasmodium falciparum* *pfmdr1* amplification, mefloquine resistance, and parasite fitness. *Antimicrob. Agents Chemother.* 53, 1509–15 (2009). <https://doi.org/10.1128/AAC.00241-08> PMID: 19164150

43. Gadalla NB, Adam I, Elzaki SE, et al. Increased *pfmdr1* copy number and sequence polymorphisms in *Plasmodium falciparum* isolates from Sudanese malaria patients treated with Artemether-Lumefantrine. *Antimicrob. Agents Chemother.* 55, 5408–11 (2011). <https://doi.org/10.1128/AAC.05102-11> PMID: 21896916
44. Witkowski B, Nicolau ML, Soh PN, et al. *Plasmodium falciparum* isolates with increased *pfmdr1* copy number circulate in West Africa. *Antimicrob. Agents Chemother.* 54, 3049–51 (2010). <https://doi.org/10.1128/AAC.00209-10> PMID: 20404118
45. Auburn S, Serre D, Pearson RD, Amato R, Sriprawat K, To S, et al. Genomic analysis reveals a common breakpoint in amplifications of the *Plasmodium vivax* multidrug resistance 1 locus in Thailand. *J. Infect. Dis.* 214, 1235 (2016). <https://doi.org/10.1093/infdis/jiw323> PMID: 27456706
46. Hester J, Chan ER, Menard D, Mercereai-Puijalón O, Barnell J, Zimmerman PA, et al. De novo assembly of a field isolate genome reveals novel *Plasmodium vivax* erythrocyte invasion genes. *PLoS Negl. Trop. Dis.* 7, e2569 (2013). <https://doi.org/10.1371/journal.pntd.0002569> PMID: 24340114
47. Roesch C, Popovici J, Bin S, Run V, Kim S, Ramboarina S, et al. Genetic diversity in two *Plasmodium vivax* protein ligands for reticulocyte invasion. *PLoS Negl. Trop. Dis.* 12, e0006555 (2018). <https://doi.org/10.1371/journal.pntd.0006555> PMID: 30346980
48. Ntumngia FB, Thomson-Luque R, Torres Lde M, Guanlan K, Carvalho LH, Adams JH. A novel erythrocyte binding protein of *Plasmodium vivax* suggests an alternate invasion pathway into Duffy-positive reticulocytes. *MBio* 7, e01261 (2016). <https://doi.org/10.1128/mBio.01261-16> PMID: 27555313
49. King CL, Adams JH, Xianli J, Grimberg BT, McHenry AM, Greenberg LJ, Siddiqui A, Howes RE, da Silva-Nunes M, Ferreira MU, Zimmerman PA. Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to *Plasmodium vivax* malaria. *Proc. Natl. Acad. Sci. USA* 108, 20113 (2011). <https://doi.org/10.1073/pnas.1109621108> PMID: 22123959
50. Chittoria A, Mohanty S, Jaiswai YK, Das A. Natural selection mediated association of the Duffy (FY) gene polymorphisms with *Plasmodium vivax* malaria in India. *PLoS ONE* 7, e45219 (2012). <https://doi.org/10.1371/journal.pone.0045219> PMID: 23028857
51. Kasehagen LJ, Mueller I, Kiniboro B, Bockarie MJ, Reeder JC, Kazura JW, et al. Reduced *Plasmodium vivax* erythrocyte infection in PNG Duffy-negative heterozygotes. *PLoS ONE* 2, e336 (2007). <https://doi.org/10.1371/journal.pone.0000336> PMID: 17389925
52. Cavasini CE, de Mattos LC, Couto AA, Couto VS, Couto Y, Moretti LJ, Bonini-Domingos CR, Rossit AR, Castiljo L, Machado RL. Duffy blood group gene polymorphisms among malaria vivax patients in four areas of the Brazilian Amazon region. *Malar. J.* 19, 167 (2007).
53. Maestre A, Muskus C, Duque V, Agudelo O, Liu P, Takegi A, et al. Acquired antibody responses against *Plasmodium vivax* infection vary with host genotype for Duffy Antigen Receptor for Chemokines (DARC). *PLoS ONE* 5, e11437 (2010). <https://doi.org/10.1371/journal.pone.0011437> PMID: 20664684